Pfizer Inc. (NYSE:PFE) Stock Holdings Decreased by First Financial Bank Trust Division

First Financial Bank Trust Division lowered its stake in Pfizer Inc. (NYSE:PFE) by 3.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 219,957 shares of the biopharmaceutical company’s stock after selling 6,912 shares during the period. First Financial Bank Trust Division’s holdings in Pfizer were worth $6,366,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of PFE. Olistico Wealth LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at about $29,000. Quarry LP bought a new stake in shares of Pfizer during the 2nd quarter valued at about $31,000. Creekmur Asset Management LLC bought a new stake in shares of Pfizer during the 4th quarter valued at about $32,000. Finally, Trivant Custom Portfolio Group LLC grew its position in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on PFE shares. Wells Fargo & Company boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. StockNews.com cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Tuesday. Barclays upped their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, September 16th. Nine analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Trading Down 0.2 %

Shares of NYSE:PFE opened at $28.61 on Thursday. The company has a 50 day moving average of $29.25 and a 200-day moving average of $28.31. The firm has a market cap of $162.10 billion, a P/E ratio of -476.67, a P/E/G ratio of 1.25 and a beta of 0.68. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $34.11. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same period in the prior year, the business earned $0.67 earnings per share. The business’s quarterly revenue was up 2.1% on a year-over-year basis. As a group, analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.